Navigation Links
Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
Date:7/11/2011

ulatory cell activation, known to have immune suppressive effects, adds to our prior findings and suggests Ii-Key hybrids could have potential in the field of cancer immunotherapy," he added.  Jos van der Woert, who has accepted the position of Chief Executive Officer of Antigen Express, commented:  "This study further supports the differentiating profile of AE37 with other cancer immunotherapies and provides additional momentum to AE37's clinical development."

Prior clinical studies of an Ii-Key hybrid peptide being developed by Antigen Express, AE37, including a Phase I trial in patients with prostate cancer and a separate trial in patients with breast cancer, have been reported as the subject of four publications in leading peer-reviewed journals.  In brief, those studies showed that AE37 is safe, well-tolerated, and produced immunological responses that were above-and-beyond what had been hoped for.  When compared with two other HER-2 vaccines that have been evaluated in the clinic, AE37 produced the greatest HER-2-related delayed-type hypersensitivity (DTH) reactions in immunized patients.  Of all immunological responses examined in patients undergoing active immunotherapy for cancer, it has been argued that a strong DTH response most reliably predicts efficacy.  In addition, it was found that AE37 was the only peptide able to generate an immunological response when administered without an adjuvant (co-stimulatory agent).  Finally, (as indicated above) AE37 also was the only peptide shown to decrease the level of T regulatory cells.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to the current standard of care treatment.  There are currently over 200 patients enrolled in the study with either node pos
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
2. Generex Provides Clarification of Facts
3. Generex Announces Results of Annual Stockholders Meeting
4. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
5. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
6. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
7. Generex Announces $3.0 Million Capital Investment
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
10. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
11. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Opertech Bio, Inc., a company that ... approach to sensory evaluation, today announced the issuance ... Patent and Trademark Office, encompassing high-throughput sensory discrimination ... taste evaluation technology called Microtiter Operant Gustometer or ... for rapid characterization of taste sensory properties,” said ...
(Date:9/2/2014)... - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that ... will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a biotechnology ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
(Date:9/2/2014)... The inventors of tinAway, a novel ... are seeking support for development costs through a crowdfunding ... http://igg.me/at/tinaway ), was launched on September 1, 2014. , ... and is based on ten years of neuroscience ... and software engineers, Dr. Ian Dixon and Mr. Tony ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... on,endocrinology and oncology, today reported financial and operating results,for the ... Highlights, - Advancement of cetrorelix Phase 3 program ... trial: patient enrollment completed; - ...
... ST. LOUIS, Aug. 12 At the Board ... quarterly cash dividend of,$.13 per share. The dividend ... record on September 2, 2008., About Sigma-Aldrich: ... company. Our biochemical and organic chemical products and ...
... LI-COR Biosciences continues to,expand its offering of ... new IRDye(R) 680 Donkey Anti-Chicken IgG, IRDye ... IgG, and IRDye 800CW Goat,Anti-Rat IgG antibodies ... detection for multiple applications including,quantitative Westerns, In-Cell ...
Cached Biology Technology:AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results 7
(Date:8/29/2014)... understand how the repeated climatic shifts over the ... of genetic diversity, a team of researchers led ... Ana Carnaval developed a new biodiversity metric called ... which the genetic variation within species is restricted ... professor of biology, and 14 other researchers from ...
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... fittest survive has been called into question by new research ... A collaboration between the Universities of Exeter and Bath in ... in the US, challenges our current understanding of evolution by ... The work represents a new approach to studying evolution that ...
... done by Mark Lusk and colleagues at the Colorado ... solar cells. Their latest work describes how the size ... energy to electrons to generate electricity. The results ... ACS Nano . The advance provides evidence ...
... NeoProteomics Inc., a biomarker development and software ... Case Western Reserve University. The deal has potential ... diabetes, and inflammatory diseases. Proteomics is the ... structures of biological systems. NeoProteomics, founded in 2006 ...
Cached Biology News:Research shows not only the fittest survive 2Size matters: Smaller particles could make solar panels more efficient 2Case Western Reserve and NeoProteomics announce exclusive option 2
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Request Info...
Biology Products: